Origen Therapeutics is focused on the development and production of

next generation antibody therapeutics.

Origen Therapeutics is a leader in next generation immunotherapeutics through discovery and production of novel antibody therapeutics derived from the company’s proprietary avian transgenic technology platform. The focus of the company is the development of fully human sequence polyclonal antibodies for human therapeutic use, particularly to fight infectious disease and cancer. Polyclonal antibodies more closely mimic the body’s own natural immune defenses than the current standard of immunotherapy, monoclonal antibodies, and are therefore considered to have significant advantages.  The technology platform can also be applied to the production of more effective and less expensive biopharmaceutical proteins. In addition to development of its own proprietary products, Origen expects to create significant corporate alliances with biotechnology and large pharmaceutical companies for the commercialization of its products.

Origen’s business is characterized by:

• Product development programs that address large market opportunities and important healthcare needs.

• A broad-based technology platform offering a wide array of pharmaceutical products.

• A strong intellectual property position through exclusive license along with issued and pending patents underpinning the company’s technology platform.

• A management team with significant experience in the areas of animal transgenics, immunotherapeutics and emerging biotechnologies.